The deputy general manager of "Pharmaceutical Brother" is replaced, or accelerate the promotion of research and development

【Pharmaceutical Network Industry News】The change of senior executives in the pharmaceutical industry continues
.
On the evening of October 10, Hengrui Pharmaceutical announced that Tao Weikang, deputy general manager of the company, resigned
due to personal reasons.
Then there was internal information that He Feng was appointed as the new deputy general manager and will undertake the new drug research and development and R&D management of
Shanghai Hengrui R&D Center.
It is understood that Tao Weikang, who left the company, has served as deputy general manager of Shanghai Hengrui Pharmaceutical Co.
, Ltd.
, CEO of R&D center since 2014, and deputy general manager
of the company since July 2015.
According to the 2021 annual report, Tao Weikang's total pre-tax remuneration for the whole year of 2021 was 4.
8438 million yuan
.
The newly appointed Deputy General Manager He Feng joined Shanghai Hengrui Pharmaceutical Co.
, Ltd.
as Deputy General Manager in 2015 and served as the Chief Executive Officer
of Shanghai Hengrui Pharmaceutical Co.
, Ltd.
from 2022.
From his past experience, He Feng has worked in many multinational pharmaceutical companies such as Bristol-Myers Squibb, Novartis and AbbVie, mainly engaged in the research and development of innovative drugs in the fields of viruses, cancer, kidney disease and other diseases
.
In this regard, the industry believes that the deputy general manager of Hengrui will be replaced or accelerate the company's research and development upgrades
.
In recent years, generic drugs have been under continuous pressure due to the impact of collection, medical insurance negotiations have accelerated the entry of innovative drugs into the medical insurance directory, and pharmaceutical companies are facing new innovation dilemmas
.
At present, Hengrui is in the stage of innovation and transformation, and the company vigorously develops innovative drugs and continuously increases R&D investment
.
From 2019 to 2021, the company's R&D investment was 3.
896 billion yuan, 4.
989 billion yuan and 6.
203 billion yuan, respectively, with a total investment of 15.
088 billion yuan
in three years.
In the first half of 2022, the company's cumulative R&D investment reached 2.
909 billion yuan, an increase of 12.
74% year-on-year, and the proportion of R&D investment in sales revenue increased to 28.
44% year-on-year, of which the expensed R&D investment was 2.
184 billion yuan, and the proportion of R&D expenses in sales revenue increased to 21.
36%
year-on-year.
Up to now, the company's listed innovative drugs have increased to 11, more than 60 innovative drugs under research in the first half of the year, and more than 260 clinical studies
have been carried out at home and abroad.
But innovative drugs also face the risk of price cuts in health care negotiations
.
According to the 2022 interim report, Hengrui Pharmaceutical achieved sales revenue of 5.
207 billion yuan, an increase of 43.
80%
year-on-year.
Among them, apatinib, pirrotinib, thiopepfergastine, rimazoram, fluzopali, hetrapopid and other innovative drugs to implement new medical insurance negotiation prices, medical insurance sales prices fell by an average of 33%, coupled with product access difficulties and other factors, innovative drug revenue growth is slower, and even individual innovative drugs due to a large price decline, the first half of the sales amount has declined
.
In order to promote the industrial layout, Hengrui threw out an equity incentive plan in September this year, and Hengrui Pharmaceutical intends to grant no more than 12 million shares to no more than 1158 core employees, with a grant price of 4.
406 yuan per share
.
The incentive strength of the employee stock ownership plan is significantly larger than the incentive plan thrown out in August 2020 (25.
736 million restricted shares were granted to 1302 eligible incentive recipients at a price of 46.
91 yuan per share
).
According to the performance appraisal objectives, at the company level, the assessment year is from 2022 to 2024, the company's innovative drug revenue is not less than 8.
5 billion yuan, 10.
5 billion yuan, 13 billion yuan, the number of new molecular entities IND approved is not less than 10, 11, 12, and the number of NDA applications declared and accepted by innovative drugs is not less than 6, 7, and 8
.
It can be seen that innovative drugs are still the focus
of Hengrui's efforts.
In addition to innovation and transformation, a series of executive changes have also occurred within the company, including Zhang Yuehong, deputy general manager in charge of personnel, and Zou Jianjun, deputy general manager who is also the chief medical officer, who has resigned
.
At the same time, Zhang Xiaojing was appointed as deputy general manager and chief medical executive officer (oncology), and Wang Quanren was appointed as deputy general manager to promote the company's clinical research and development work
.
In addition, Dai Hongbin, the former deputy general manager of the company who has served for 22 years and has rich experience in operation and
management, was promoted to general manager.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.